Fubotv earnings beat by $0.10, revenue topped estimates
Akero Therapeutics (NASDAQ:AKRO) Senior Vice President, Commercial Strategy, Patrick Lamy, sold 875 shares of common stock on June 20, 2025, at a price of $54.59, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the transaction amounted to $47766. The transaction occurs as the stock trades near its 52-week high of $58.40, having delivered an impressive 133% return over the past year. According to InvestingPro, analysts maintain a strong buy consensus with a high price target of $109.
Following the transaction, Lamy directly owns 31698 shares of Akero Therapeutics.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, in accordance with Akero Therapeutics’ sell-to-cover policy.
In other recent news, Akero Therapeutics has been in the spotlight due to its financial and clinical developments. The company recently reported first-quarter 2025 earnings, revealing $1.1 billion in cash reserves, which is expected to support operations through 2028. Akero’s Phase 2b SYMMETRY trial results published in the New England Journal of Medicine indicated promising outcomes for its drug efruxifermin (EFX) in treating liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). The study showed significant improvements in liver fibrosis metrics, with EFX demonstrating a favorable safety profile.
Analysts have been adjusting their outlooks on Akero, with Jefferies maintaining a Buy rating and a $75 price target, citing the robust data from the EASL conference. Citi also kept a Buy rating but slightly reduced the price target from $80 to $78, noting the need for comprehensive liver outcomes data for FDA approval. Meanwhile, Morgan Stanley (NYSE:MS) adjusted its price target from $90 to $84, maintaining an Overweight rating, reflecting a cautious stance on the EFX product’s market entry timeline.
Clear Street initiated coverage with a Buy rating and a $49 price target, emphasizing EFX’s potential in treating different stages of NASH. The firm highlighted EFX’s "best-in-class potential" and significant trial results, positioning it competitively in the market. Akero’s ongoing Phase 3 SYNCHRONY program, with results expected in the first half of 2027, continues to draw attention from investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.